论文部分内容阅读
目的通过研究Cyclin A1、Cyclin D在乳腺癌患者新辅助化疗前后的相关性,探索Cyclin A1、Cyclin D表达及相关性在乳腺癌新辅助化疗中的意义。方法收集河南省肿瘤医院2008年8月—2011年7月收治的行TEC/PEC新辅助化疗的乳腺癌患者的临床及病理学信息,并对对应的石蜡标本进行Cyclin A1、Cyclin D的免疫组化化学染色,采用秩和检验和Spearman相关性分析Cyclin A1、Cyclin D表达的相关性,及预后的影响,并进行亚组分析。结果在204例接受新辅助化疗的患者中,在CR或PR组中,在化疗前后Cyclin A1、Cyclin D的表达具有显著差异,化疗前后Cyclin A1/Ki67、Cyclin D/Ki67具有显著差异,但新辅助患者的生存时间与化疗前后Cyclin A1/Ki67、Cyclin D/Ki67差值无相关性。结论新辅助化疗前后的Cyclin A1、Cyclin D可作为明确乳腺癌新辅助疗效及药物敏感性的参考数据,但与患者生存无关。
Objective To investigate the correlation between Cyclin A1 and Cyclin D before and after neoadjuvant chemotherapy in breast cancer patients and explore the significance of expression of Cyclin A1 and Cyclin D in the neoadjuvant chemotherapy of breast cancer. Methods The clinical and pathological data of breast cancer patients undergoing TEC/PEC neoadjuvant chemotherapy from August 2008 to July 2011 in Henan Provincial Tumor Hospital were collected. Cyclin A1 and Cyclin D immunohistochemistry were performed on the corresponding paraffin specimens. Chemical staining, the rank sum test and Spearman correlation were used to analyze the correlation between the expression of Cyclin A1 and Cyclin D, and the influence of prognosis. Subgroup analysis was performed. Results Among 204 patients receiving neoadjuvant chemotherapy, the expression of Cyclin A1 and Cyclin D were significantly different before and after chemotherapy in CR or PR group. Cyclin A1/Ki67 and Cyclin D/Ki67 were significantly different before and after chemotherapy. There was no correlation between the survival time of adjuvant patients and the difference of Cyclin A1/Ki67 and Cyclin D/Ki67 before and after chemotherapy. Conclusion Cyclin A1 and Cyclin D before and after neoadjuvant chemotherapy can be used as reference data to clarify the neoadjuvant efficacy and drug sensitivity of breast cancer, but has nothing to do with survival.